MIRA updates on Ketamir-2 Phase 1 progress, plans Phase IIa in neuropathic pain by end of 2025

MIRA PHARMACEUTICALS, INC.

Participating in BIO International Convention June 16-19, 2025 for partnering and licensing discussions.
Second dosing cohort of Ketamir-2 Phase 1 completed; company preparing to initiate third cohort.
Phase IIa trial in neuropathic pain expected to start by end of 2025.
Preclinical studies ongoing for PTSD and topical formulation for localized inflammatory pain.
Finalizing regulatory filings for SKNY acquisition; SKNY-1 targets smoking cessation and obesity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.